Vivus Sinks After Diet Drug Ingredient Linked to Oral Clefts
This article is for subscribers only.
Vivus Inc., maker of an experimental weight-loss pill, plunged the most in 17 months after an ingredient in the medicine was shown to be associated with oral clefts in babies whose mothers took it in pregnancy.
Vivus dropped 17 percent to $8.68 at the close of trading in New York, for the biggest decline since July 2010. The shares of the Mountain View, California-based company are down 7.4 percent this year.